SCHEMBL4409709

SCHEMBL4409709

Cc1cc(-c2cccc(C(F)(F)F)c2)nc(N)c1C(=O)N1CCC(N2CCCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ACACB O00763 5/20 0.48
ACACA Q13085 5/20 0.48
ATR Q13535 1/20 0.45
TRPV4 Q9HBA0 6/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
L3MBTL3 Q96JM7 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
CCR5 P51681 1/20 0.43
TACR2 P21452 1/20 0.42
TACR3 P29371 1/20 0.42
KCNH2 Q12809 1/20 0.42
CACNA1C Q13936 1/20 0.42
SCN5A Q14524 1/20 0.42
CYP2C9 P11712 1/20 0.42
UCHL1 P09936 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083693 0.92 ACACB (0.50) ACACBACACATRPV4IRAK4L3MBTL3
SCHEMBL1083747 0.90 ACACB (0.49) ACACBACACATRPV4IRAK4L3MBTL3
SCHEMBL1083730 0.88 ACACB (0.47) ACACBACACATRPV4IRAK4L3MBTL3
SCHEMBL1083746 0.85 ACACB (0.45) ACACBACACATRPV4IRAK4L3MBTL3
SCHEMBL1421823 0.85 ACACB (0.45) ACACBACACATRPV4IRAK4L3MBTL3
SCHEMBL1083719 0.85 CCR5 (0.51) TRPV4IRAK4L3MBTL3L3MBTL1CCR5
SCHEMBL1422612 0.84 ACACB (0.44) ACACBACACATRPV4IRAK4CCR5
SCHEMBL1083697 0.82 L3MBTL3 (0.50) ACACBACACATRPV4IRAK4L3MBTL3
SCHEMBL1420845 0.82 IRAK4 (0.44) ACACBACACAATRTRPV4IRAK4
SCHEMBL1083710 0.81 CCR5 (0.48) TRPV4IRAK4L3MBTL3L3MBTL1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227613-B2 Heteroaryl carboxamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
US-8227613-B2 Heteroaryl carboxamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
US-8227613-B2 Heteroaryl carboxamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed
WO-2009153182-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES CCR3, CCR2, CCR1 ACACB 2462/4885ACACA 2039/4885ATR 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.